SCHEMBL77364

SCHEMBL77364

Nc1ccc(N2CCC(=O)CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.57
ALDH1A1 P00352 9/20 0.57
GAA P10253 5/20 0.57
KDM4E B2RXH2 4/20 0.57
KMT2A Q03164 3/20 0.57
HTT P42858 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
MEN1 O00255 2/20 0.57
RECQL P46063 2/20 0.57
NPC1 O15118 1/20 0.57
USP2 O75604 1/20 0.57
TP53 P04637 1/20 0.57
POLB P06746 1/20 0.57
THRB P10828 1/20 0.57
ALOX15 P16050 1/20 0.57
RAB9A P51151 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
HSD17B10 Q99714 1/20 0.57
LMNA P02545 7/20 0.55
GFER P55789 6/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6073799 0.98 MAPT (0.61) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL7983473 0.88 MAPT (0.48) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL25827545 0.82 L3MBTL1 (0.56) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL23347931 0.81 MAPT (0.77) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL7043679 0.81 MAPT (0.77) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL6151120 0.81 MAPT (0.77) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL26821274 0.79 MGLL (0.50) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL7284125 0.78 MAPT (0.50) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL20907468 0.78 LMNA (0.54) MAPTALDH1A1KDM4EKMT2AHTT
SCHEMBL1645442 0.78 MAPT (0.57) MAPTALDH1A1GAAKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4658940-B2 2011-03-23 JP claimed
EP-1636216-B1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-07-21 EP claimed
US-7741341-B2 Benzimidazole-derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-22 US claimed
JP-2006528213-A 2006-12-14 JP claimed
EP-1636216-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-22 EP claimed
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-13 US claimed
WO-2004101553-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO claimed
US-20030144326-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH 2003-07-31 US claimed
US-20020028835-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH 2002-03-07 US claimed
US-20240360146-A1 BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2024-10-31 US disclosed
CN-115557933-B Bruton tyrosine kinase and mutant degradation agent, composition and application thereof 杭州和正医药有限公司 2024-08-16 CN disclosed
WO-2024146502-A1 WEE1 DEGRADING COMPOUNDS BEIJING NEOX BIOTECH LIMITED (CN) 2024-07-11 WO disclosed
EP-4342892-A1 BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2024-03-27 EP disclosed
WO-2024059808-A1 WEE1 INHIBITORS AND METHODS FOR TREATING CANCER RECURIUM IP HOLDINGS, LLC (US) 2024-03-21 WO disclosed
WO-2002006232-A1 CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed
WO-2001047919-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER AKTIENGESELLSCHAFT (DE) 2001-07-05 WO disclosed
CN-1051308-C Oxazolidin-2-one derivatives HOFFMANN LA ROCHE (CH) 2000-04-12 CN disclosed
EP-0657440-B1 Oxazolidine-2-one derivatives as MAO inhibitors HOFFMANN LA ROCHE (CH) 2000-04-05 EP disclosed
US-5574055-A COGNITIVE AND NEURODEGENERATIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 1996-11-12 US disclosed
EP-0657440-A1 Oxazolidine-2-one derivatives F. HOFFMANN-LA ROCHE AG (CH) 1995-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144326-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 MAPT 565/4885ALDH1A1 1091/4885GAA 1992/4885
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors F12, F11, F5 MAPT 4847/4885ALDH1A1 1259/4885GAA 41/4885
US-20240360146-A1 BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF BTK, ZAP70, SYK MAPT 4559/4885ALDH1A1 4835/4885GAA 1642/4885
US-20020028835-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 MAPT 565/4885ALDH1A1 1091/4885GAA 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.